局部晚期食管鳞癌术前同期放化疗疗效及预后因素分析

目的评价局部晚期食管鳞癌术前同期放化疗治疗效果和影响预后的因素。方法回顾分析2007-2017年郑州大学附属肿瘤医院收治的148例经术前同期放化疗并手术治疗的局部晚期食管鳞癌患者资料,化疗采用氟尿嘧啶+顺铂或紫杉醇+顺铂方案,放疗剂量为36~40Gy,常规分割。Kaplan-Meier法计算生存率并Logrank检验及单因素分析,Cox模型多因素分析。结果全组1、3、5年总生存率分别为74%、51%、51%,无瘤生存率分别为60%、51%、45%;中位生存期为72.4个月,无瘤生存期为60.1个月。pCR与非pCR的1、3、5年总生存率分别为86%、70%、70%与70%、44%、43%(P=0.002),无瘤生存率分别为76%、71%、68%与53%、43%、37%(P=0.002)。pN(-)与pN(+)的1、3、5年总生存率分别为83%、56%、55%与50%、38%、38%(P=0.004),无瘤生存率分别为66%、56%、51%与43%、38%、31%(P=0.006)。多因素分析显示是否pCR和pN状态是影响总生存和无瘤生存的因素(P=0.012、0.011和P=0.025、0.033)。结论术前同期放化疗治疗局部晚期食管鳞癌疗效显著,是否pCR和pN状态是预后影响因素。

Analysis of the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Objective To evaluate the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Methods The clinical data of a total of 148 patients with locally advanced esophageal squamous cell carcinoma enrolled in the Affiliated Cancer Hospital of Zhengzhou University from 2007 to 2017 were retrospectively analyzed. The patients received 5-Fu/Cisplatin or Paclitaxel/Cisplatin for chemotherapies. The total treatment dose for the radiotherapy was delivered at 36-40Gy under conventional fractionation. Kaplan-Meier method was used to calculate survival rates, and Log-rank test and Cox model were performed for univariate analysis and multivariate analysis, respectively. Results The overall survival (OS) rates of 1-, 3-and 5-year were 74%, 51% and 51%, respectively, with a median survival time (MST) of 72.4 months. The carcinoma/disease-free survival (DFS) rates for 1, 3, 5 years were 60%, 51%, 45%, respectively, with a median time of 60.1 months. The 1-, 3-and 5-year OS rates of the pCR group were 86%, 70%, 70%, the ones of which in the non-pCR group were 70%, 44%, 43%, respectively (P=0.002). The 1-, 3-and 5-year DFS rates were 76%, 71%, 68% for the pCR group, and 53%, 43%, 37% for the non-pCR group, respectively (P=0.002). In pN(-) group and pN(+) group, the 1-, 3-and 5-year OS rates were 83%, 56%, 55% and 50%, 38%, 38%(P=0.004), respectively. Further, the 1-, 3-and 5-year DFS rates were 66%, 56%, 51% for the pN(-) group, and 43%, 38%, 31% for the pN(+) group (P=0.006), respectively. Multivariate analysis revealed that pCR and pN status were independent prognostic factors for OS and DFS (P=0.012, 0.011 and P=0.025, 0.033). Conclusion Neoadjuvant chemoradiotherapy demonstrated significant therapeutic effects in the treatment of locally advanced esophageal squamous cell carcinoma, while pCR and pN status served as independent prognostic factors.